High serum levels of follistatin in patients with ovarian cancer

Journal of International Medical Research

Volumn 40, Issue 3, 2012, Pages 877-886

  Ren, P ^a   Chen, F F ^b   Liu, H Y ^c   Cui, X L ^c   Sun, Y ^c   Guan, J L ^b   Liu, Z H ^c   Liu, Jian Guo ^a   Wang, Y N ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c Basic Medical College   (China)

Author keywords

Cancer Antigen 125; Diagnosis; Follistatin; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; FOLLISTATIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OVARY; OVARY CANCER; OVARY CYST; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA;

EID: 84863087905     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000306     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Buys SS, Partridge E, Black A, et al for the PLCO Project Team: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305: 2295-2303.
3. Robertson DM, Klein R, de Vos FL, et al: The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 1987; 149: 744-749.
4. Ueno N, Ling N, Ying SY, et al: Isolation and partial characterization of follistatin: a singlechain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA 1987; 84: 8282-8286.
5. Maguer-Satta V, Bartholin L, Jeanpierre S, et al: Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGF β family. Exp Cell Res 2003; 282: 110-120.
6. Nakamura T, Hasegawa Y, Sugino K, et al: Follistatin inhibits activin-induced differentiation of rat follicular granulosa cells in vitro. Biochim Biophys Acta 1992; 1135: 103-109.
7. Wakatsuki M, Shintani Y, Abe M, et al: Immunoradiometric assay for follistatin: serum immunoreactive follistatin levels in normal adults and pregnant women. J Clin Endocrinol Metab 1996; 81: 630-634.
8. Liu ZH, Shintani Y, Sakamoto Y, et al: Effects of LHRH, FSH and activin A on follistatin secretion from cultured rat anterior pituitary cells. Endocr J 1996; 43: 321-327.
9. Petru E, Lück HJ, Stuart G, et al: Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol 2009; 143: 69-74.
10. Florio P, Reis FM, Torres PB, et al: High serum follistatin levels in women with ovarian endometriosis. Hum Reprod 2009; 24: 2600-2606.
11. van Ingen HE, Chan DW, Hubl W, et al: Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125. Clin Chem 1998; 44: 2530-2536.
12. Liu HY, Chen FF, Ge JY, et al: Expression and localization of activin receptor-interacting protein 2 in mouse tissues. Gen Comp Endocrinol 2009; 161: 276-282.
13. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
14. Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6: e1000114.
15. Schneyer AL, Fujiwara T, Fox J, et al: Dynamic changes in the intrafollicular inhibin/ activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab 2000; 85: 3319-3330.
16. Harrison CA, Gray PC, Vale WW, et al: Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005; 16: 73-78.
17. Di Simone N, Crowley WF Jr, Wang QF, et al: Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996; 137: 486-494.
18. Xu G, Zhou H, Wang Q, et al: Activin receptorlike kinase 7 induces apoptosis through upregulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines. Mol Cancer Res 2006; 4: 235-246.
19. Leung PH, Salamonsen LA, Findlay JK: Immunolocalization of inhibin and activin subunits in human endometrium across the menstrual cycle. Hum Reprod 1998; 13: 3469-3477.
20. Ingman WV, Jones RL: Cytokine knockouts in reproduction: the use of gene ablation to dissect roles of cytokines in reproductive biology. Hum Reprod Update 2008; 14: 179-192.
21. Kimura F, Bonomi LM, Schneyer AL: Follistatin regulates germ cell nest breakdown and primordial follicle formation. Endocrinology 2011; 152: 697-706.
22. Do TV, Kubba LA, Antenos M, et al: The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology 2008; 149: 3809-3816.
23. Mabuchi Y, Yamoto M, Minami S, et al: Immunohistochemical localization of inhibin and activin subunits, activin receptors and Smads in ovarian endometriosis. Int J Mol Med 2010; 25: 17-23.
24. Urban N, Drescher C: Potential and limitations in early diagnosis of ovarian cancer. Adv Exp Med Biol 2008; 622: 3-14.
25. Gupta D, Lis CG: Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. J Ovarian Res 2009; 2: 13.
26. Helzlsouer KJ, Bush TL, Alberg AJ, et al: Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 1993; 269: 1123-1126.
27. Skates SJ, Jacobs IJ, Knapp RC: Tumor markers in screening for ovarian cancer. Methods Mol Med 2001; 39: 61-73.